Episode 172: The mRNA gold rush, Delta's alarming rise, & the next treatment for Alzheimer's

First, we dive into the potential of mRNA, a technology that proved itself with Covid-19 vaccines and is now seeding a pharmaceutical gold rush. Then, STAT's Helen Branswell joins us to discuss the state of the pandemic, the implications of the Delta variant, and the debate around booster shots. We also dissect the week's news in biotech, included Amgen's tax problems, a meltdown in synthetic biology, and the latest on Aduhelm.